Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

January 16, 2018

ANCA May Affect Large as Well as Small Blood Vessels, Case Studies Show

News

ANCA vasculitis may trigger inflammation in large blood vessels as well as the small ones the disease is associated with, Japanese researchers reported after noting that three patients had developed ... Read more

January 9, 2018

EMA Accepts Conditional Application for ANCA Treatment Avacopan

News

The European Medicines Agency (EMA) has accepted for review ChemoCentryx’s application to approve Avacopan (CCX168) as a treatment for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The company, with its partner ... Read more

December 19, 2017

Trial to Explore If Low-dose Glucocorticoids May Improve Safety of ANCA Vasculitis Treatment

News

A clinical trial will assess whether low-dose glucocorticoids and Rituxan (rituximab) may be used as a safer way to treat ANCA-associated vasculitis (AAV). Researchers at Chiba University Hospital in Japan ... Read more

December 5, 2017

ANCA Vasculitis Treatment Research Advancing, Mayo Researchers Say

News

While the treatment of ANCA-associated vasculitis has taken strides away from highly toxic immunosuppressants to include an array of approaches based on biological drugs, there is plenty of room ... Read more

October 5, 2017

Maintenance Treatment After Rituxan for ANCA-associated Vasculitis Not Needed, Researchers Argue

News

Certain types of patients with ANCA-associated vasculitis do not require maintenance therapy if treated with a specific Rituxan (rituximab) approach, according to researchers at the University of Turin in ... Read more

August 17, 2017August 17, 2017

Longer Treatment Could Help ANCA-Associated Vasculitis Patients Avoid Relapse, Study Finds

News

People with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis have a lesser chance of relapse if they continue with maintenance treatment for two years instead of one, according to the results ... Read more

July 11, 2017

Nucala Triggered Remission in Eosinophilic Granulomatosis with Polyangiitis, But Not All Benefit

News

Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a ... Read more